Single Hormone Receptor Positive Breast Cancer: Clinical Significance and Impact on Outcome

Background: Single hormone receptor (HR) positive breast cancers form nearly one out of ten of the most common female malignancy. Yet, no specific management strategies available in our battle with this distinct breast cancer subtype. Objective: This study aimed at unveiling the clinico-pathologic characteristics and prognosis of both single estrogen receptor (ER)-positive and single-progesterone receptor (PR)-positive breast cancers. Patients and Methods: Epidemiologic, clinico-pathologic and survival data of 785 single HR-positive breast cancer included female patients had been studied. Patient records, from January 2010 to December 2020, were retrieved from Oncology Center Mansoura University (OCMU)' system (Medical Oncology Clinic). Results: In this study, the incidence of single HR-positive breast cancer was 12.15% (8.47% single ER-positive and 3.68% single PR-positive). Statistical differences had been observed among both single-HR positive subgroups regarding age, menopausal state, tumor size, axillary lymph node involvement, distant metastases pattern and certain management aspects. Better survival indices were observed with single PR-positive subgroup. Conclusion: Both single HR-positive subtypes had distinct clinco-pathologic and prognostic significance. Further research is needed for optimizing management strategies.